Steven Leonard Chapman Sells 3,960 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,960 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $468,111.60. Following the completion of the transaction, the chief executive officer now owns 189,762 shares in the company, valued at $22,431,766.02. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total value of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total value of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.

Natera Trading Up 1.6 %

Shares of NASDAQ:NTRA opened at $126.73 on Thursday. Natera, Inc. has a 52 week low of $37.67 and a 52 week high of $133.54. The company’s 50 day moving average is $123.31 and its two-hundred day moving average is $111.82. The company has a market cap of $15.67 billion, a PE ratio of -51.73 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.97) earnings per share. Equities analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $150.00 price target on shares of Natera in a research note on Friday, September 13th. UBS Group cut their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday. TD Cowen lifted their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, BTIG Research increased their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $125.69.

Hedge Funds Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in NTRA. Quent Capital LLC grew its position in shares of Natera by 3.2% in the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after buying an additional 99 shares during the last quarter. GAMMA Investing LLC boosted its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. Private Advisor Group LLC increased its position in shares of Natera by 5.2% during the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after purchasing an additional 135 shares in the last quarter. Finally, Lake Street Advisors Group LLC lifted its holdings in shares of Natera by 7.4% in the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 156 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.